Texolite Drywall Surfacer

Product Description

Texolite Drywall Surfacer was a finishing and texturing compound manufactured by United States Gypsum Company (USG) during the period from 1961 through 1972. The product was designed for use as a surface preparation and finishing material in drywall construction, intended to smooth, coat, and texture gypsum wallboard prior to painting or final finishing. It was marketed as a ready-mix or powder-based compound suitable for both residential and commercial construction applications.

United States Gypsum was among the largest manufacturers of building materials in the United States during the mid-twentieth century, and its product lines reached construction sites, industrial facilities, and manufacturing plants nationwide. Texolite Drywall Surfacer was part of a broader category of joint and finishing compounds that the company produced during an era when asbestos was widely incorporated into construction materials for its binding properties, fire resistance, and ability to improve the workability and durability of mixed compounds. The product remained in production for approximately eleven years, spanning a period during which regulatory awareness of asbestos hazards was only beginning to develop, and the use of asbestos-containing materials in building products was standard industry practice.

Asbestos Content

Texolite Drywall Surfacer contained chrysotile asbestos, the most commercially prevalent form of asbestos used in building materials throughout the twentieth century. Chrysotile, also referred to as white asbestos, is a serpentine mineral fiber that was valued in compound and texture products for its ability to reinforce the material matrix, prevent cracking, improve adhesion, and extend workability time during application.

Although chrysotile is sometimes characterized as less hazardous than amphibole asbestos varieties such as crocidolite or amosite, extensive scientific and regulatory documentation has established that chrysotile fibers are capable of causing mesothelioma, asbestosis, and lung cancer when inhaled in sufficient quantities over time. The U.S. Environmental Protection Agency (EPA) and the Occupational Safety and Health Administration (OSHA) both recognize chrysotile as a known human carcinogen with no established safe level of exposure.

In joint compounds and surfacing products such as Texolite Drywall Surfacer, chrysotile asbestos was typically incorporated during the manufacturing process as a functional additive. The fiber content in such products varied by formulation, but asbestos was a deliberate and integral ingredient, not a trace contaminant. Litigation records document that analysis of similar USG-era surfacing compounds confirmed the presence of asbestos at concentrations sufficient to generate hazardous airborne fiber levels during normal use.

How Workers Were Exposed

Industrial workers who handled, mixed, applied, or worked in proximity to Texolite Drywall Surfacer during the product’s production years from 1961 through 1972 faced potential inhalation exposure to chrysotile asbestos fibers. The nature of surfacing and texturing compounds made them particularly hazardous from an exposure standpoint, as the product required activities that could readily release asbestos fibers into the breathing zone.

When supplied in dry powder form, the process of opening bags, pouring, and mixing Texolite Drywall Surfacer generated visible dust clouds that contained respirable asbestos fibers. Even when the product was used in a pre-mixed wet state, subsequent processes including sanding, scraping, cutting, or disturbance of dried material released fibers in concentrated amounts. Applied surfaces that were later sanded smooth — a routine step in achieving a finished wall surface — were among the most significant sources of fiber release documented in industrial hygiene literature from the period.

Workers in industrial settings where drywall installation or finishing was performed as part of construction or renovation activity were exposed not only through direct handling of the product but also through secondary exposure in shared work environments. In poorly ventilated spaces, asbestos-laden dust could remain suspended in the air for extended periods, affecting workers who had no direct contact with the compound itself.

Plaintiffs alleged in civil litigation that United States Gypsum possessed internal knowledge of asbestos hazards associated with its surfacing and compound products during the period when Texolite Drywall Surfacer was in production, and that the company failed to provide adequate warnings to workers, contractors, or end users about the risks of asbestos inhalation. Plaintiffs further alleged that despite the availability of technical information linking asbestos dust to serious respiratory disease — including literature circulating within the asbestos and building products industries as early as the 1930s and 1940s — no meaningful hazard communication accompanied the product during its years of manufacture and sale.

The latency period for asbestos-related diseases is well established in medical literature as typically ranging from ten to fifty years following initial exposure. This means that individuals exposed to Texolite Drywall Surfacer during its production window of 1961 to 1972 may only have received diagnoses of mesothelioma, asbestosis, or related conditions in subsequent decades, continuing into the present day.

Because United States Gypsum has not established a dedicated asbestos bankruptcy trust fund specifically associated with Texolite Drywall Surfacer or its broader joint compound product lines under standard Tier 1 trust fund eligibility structures, legal remedies for individuals harmed by this product are pursued through civil litigation rather than trust fund claim processes.

Litigation records document that United States Gypsum and its successor entities have been named defendants in asbestos personal injury litigation related to their compound and surfacing products on numerous occasions. Plaintiffs in these cases have included workers diagnosed with mesothelioma, lung cancer, and asbestosis who alleged exposure to USG-manufactured products containing asbestos during the course of their employment in construction, industrial, and related trades.

Individuals who believe they were exposed to Texolite Drywall Surfacer and have since received a diagnosis of an asbestos-related disease should consult with a qualified asbestos litigation attorney to evaluate their legal options. Attorneys experienced in asbestos personal injury claims can assist in:

  • Documenting exposure history through employment records, co-worker testimony, and product identification evidence
  • Establishing product identification by connecting the specific product to a diagnosed illness
  • Evaluating applicable statutes of limitations, which vary by state and typically begin running from the date of diagnosis rather than the date of exposure
  • Assessing potential defendants, as multi-party litigation involving multiple manufacturers and distributors is common in asbestos cases

Because Texolite Drywall Surfacer was produced during a defined historical window, workers who used or encountered the product on job sites during the 1960s and early 1970s — and who have since developed a qualifying diagnosis — may have viable claims depending on the jurisdiction and the specific facts of their exposure history.

Given the long latency periods associated with asbestos disease, time-sensitive legal deadlines make early consultation with a qualified attorney critically important for affected individuals and their families.

This article is provided for informational reference purposes only and does not constitute legal advice. Individuals seeking guidance regarding asbestos exposure claims should consult a licensed attorney.